Literature DB >> 17713569

Clinical and molecular characterization of patients at risk for hereditary melanoma in southern Brazil.

Patricia Ashton-Prolla1, Lucio Bakos, Gerson Junqueira, Roberto Giugliani, Sergio J Azevedo, David Hogg.   

Abstract

Melanoma is the most dangerous of all common skin cancers, due to its propensity to metastasize. Therefore, identification of at-risk populations may allow early detection of disease at a curable stage. In Europe and North America, between 8-14% of melanoma patients have a family history of the disease, and a subset of these individuals possess germline mutations in the CDKN2A gene, which encodes the p16(INK4A) and p14(ARF) tumor suppressors. We identified 30 patients (29 families) from Southern Brazil, who had a family history of melanoma and/or pancreatic cancer; or a personal history of multiple primary melanoma. We screened this cohort for mutations in the CDKN2A and CDK4 genes, and detected two functional mutations: a G-34T transversion in 5'untranslated region; and a M53I alteration encoded in exon 2. Both mutants have been previously associated with melanoma and demonstrate founder effects. We conclude that germline mutations of CDKN2A occur in the Brazilian population, and that these mutations likely originated in Europe.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713569     DOI: 10.1038/sj.jid.5701030

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma.

Authors:  Alexandre Leon Ribeiro de Ávila; Ana Cristina Victorino Krepischi; Luciana Facure Moredo; Talita Ferreira Marques Aguiar; Felipe Carneiro da Silva; Bianca Costa Soares de Sá; Amanda França de Nóbrega; Maria Isabel Waddington Achatz; João Pedreira Duprat; Gilles Landman; Dirce Maria Carraro
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

2.  Epidemiology of melanoma in the South of Brazil: study of a city in the Vale do Itajaí from 1999 to 2013.

Authors:  Adma Silva de Lima; Carlos Efrain Stein; Karla Patricia Casemiro; Rodrigo Kraft Rovere
Journal:  An Bras Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.896

3.  Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma.

Authors:  Susana Puig; Miriam Potrony; Francisco Cuellar; Joan Anton Puig-Butille; Cristina Carrera; Paula Aguilera; Eduardo Nagore; Zaida Garcia-Casado; Celia Requena; Rajiv Kumar; Gilles Landman; Bianca Costa Soares de Sá; Gisele Gargantini Rezze; Luciana Facure; Alexandre Leon Ribeiro de Avila; Maria Isabel Achatz; Dirce Maria Carraro; João Pedreira Duprat Neto; Thais C Grazziotin; Renan R Bonamigo; Maria Carolina W Rey; Claudia Balestrini; Enrique Morales; Montserrat Molgo; Renato Marchiori Bakos; Patricia Ashton-Prolla; Roberto Giugliani; Alejandra Larre Borges; Virginia Barquet; Javiera Pérez; Miguel Martínez; Horacio Cabo; Emilia Cohen Sabban; Clara Latorre; Blanca Carlos-Ortega; Julio C Salas-Alanis; Roger Gonzalez; Zulema Olazaran; Josep Malvehy; Celia Badenas
Journal:  Genet Med       Date:  2015-12-17       Impact factor: 8.822

4.  Family-based whole-exome sequencing identifies rare variants potentially related to cutaneous melanoma predisposition in Brazilian melanoma-prone families.

Authors:  Felipe Fidalgo; Giovana Tardin Torrezan; Bianca Costa Soares de Sá; Bruna Durães de Figueiredo Barros; Luciana Facure Moredo; Renan Valieris; Sandro J de Souza; João Pereira Duprat; Ana Cristina Victorino Krepischi; Dirce Maria Carraro
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

5.  Management of melanoma families.

Authors:  Wilma Bergman; Nelleke A Gruis
Journal:  Cancers (Basel)       Date:  2010-04-16       Impact factor: 6.639

6.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.